Raymond James Financial Inc. Sells 100,752 Shares of Moderna, Inc. $MRNA

Raymond James Financial Inc. reduced its stake in Moderna, Inc. (NASDAQ:MRNA) by 49.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 103,497 shares of the company’s stock after selling 100,752 shares during the quarter. Raymond James Financial Inc.’s holdings in Moderna were worth $2,934,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the stock. Knuff & Co LLC boosted its position in shares of Moderna by 58.4% in the 1st quarter. Knuff & Co LLC now owns 6,140 shares of the company’s stock worth $174,000 after purchasing an additional 2,263 shares in the last quarter. Cresset Asset Management LLC bought a new stake in shares of Moderna in the 1st quarter worth approximately $522,000. American Century Companies Inc. grew its holdings in shares of Moderna by 4.1% during the first quarter. American Century Companies Inc. now owns 46,449 shares of the company’s stock valued at $1,317,000 after buying an additional 1,830 shares during the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of Moderna during the first quarter valued at approximately $339,000. Finally, Neuberger Berman Group LLC grew its holdings in shares of Moderna by 39.0% during the first quarter. Neuberger Berman Group LLC now owns 61,666 shares of the company’s stock valued at $1,748,000 after buying an additional 17,309 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on MRNA. Evercore ISI set a $32.00 price target on shares of Moderna in a report on Friday, August 1st. Bank of America cut their price target on shares of Moderna from $26.00 to $25.00 and set an “underperform” rating on the stock in a report on Tuesday, July 22nd. Morgan Stanley reiterated an “equal weight” rating and set a $32.00 price target on shares of Moderna in a report on Friday, August 1st. Wells Fargo & Company reiterated an “equal weight” rating on shares of Moderna in a report on Sunday, July 13th. Finally, William Blair reiterated a “market perform” rating on shares of Moderna in a report on Monday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, sixteen have issued a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Moderna has a consensus rating of “Hold” and a consensus price target of $42.88.

Moderna Price Performance

NASDAQ MRNA opened at $25.14 on Monday. The business’s fifty day moving average price is $28.84 and its 200-day moving average price is $28.47. The stock has a market capitalization of $9.78 billion, a price-to-earnings ratio of -3.34 and a beta of 1.93. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $79.96.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, beating the consensus estimate of ($2.99) by $0.86. The firm had revenue of $142.00 million for the quarter, compared to analysts’ expectations of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The company’s revenue was down 41.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($3.33) EPS. Moderna has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.